More than 500 listed companies disclosed annual report performance forecasts, and the pharmaceutical and biological industry earned a lot of attention

Entering the new year, the 2021 annual performance forecast of pharmaceutical companies has been released intensively
.
According to statistics from the Flush Data Center, as of now, more than 500 listed companies in the two cities have released performance forecasts for their 2021 annual reports, of which 250 are expected to increase their performance and 82 to decrease their performance
.
Judging from the industries to which the pre-increased companies belong, industries such as pharmaceuticals, biology, and electronics have performed well, and their performance has grown significantly
.
Wind information data shows that as of January 16, a total of 33 A-share listed pharmaceutical and biological companies have released 2021 performance forecasts, of which over 80% of them are pre-scheduled, earning enough attention
.
At the beginning of 2022, the author also sorted out some of the pharmaceutical companies whose net profit pre-increased last year in the article "13 Pharmaceutical Companies Disclose Annual Report Forecast, 5 Estimated Net Profit Doubled", which attracted widespread attention in the industry
.
More than 500 listed companies have disclosed annual report performance forecasts, and the pharmaceutical and biological industry has earned a lot of attention
.
On January 19, at least five pharmaceutical companies, including Haichen Pharmaceutical, WuXi AppTec, Jiuzhou Pharmaceutical, and Yabao Pharmaceutical, intensively released their 2021 annual report performance forecasts, and many of them predicted that their net profit would increase by more than 100% in 2021.
%
.
For example, Haichen Pharmaceutical expects to achieve a net profit of 288.
3527 million yuan to 298.
9612 million yuan from January 1, 2021 to December 31, 2021, an increase of 422.
09% to 441.
30%, and a net profit of 55.
2301 million yuan in the same period last year; Medicilon expects the net profit for 2021 to be 278 million to 291 million yuan, an increase of 115% to 125%, and a net profit of 129.
3863 million yuan in the same period last year
.
On January 18, Shuangcheng Pharmaceutical, Panlong Pharmaceutical, Sannuo Bio, Jimin Medical, Gongdong Medical, etc.
released the 2021 annual performance forecast.
Among them, Panlong Pharmaceutical, Jimin Medical, Gongdong Medical, etc.
Many companies have good results
.
On January 17, Shuo Shi Bio announced a significant increase in performance.
It is expected that from January 1, 2021 to December 31, 2021, the company's net profit will be 1.
13 billion yuan to 1.
35 billion yuan, an increase of 37.
88% to 64.
72%.
Net profit was 819 million yuan
.
In addition, Sanyou Medical also disclosed the 2021 annual report performance forecast.
It is expected to achieve a net profit of 176 million to 190 million yuan in 2021, an increase of 48.
45% to 60.
26%, and a net profit of 118.
5588 million yuan in the same period last year
.
From the perspective of pharmaceutical companies with recent performance forecasts, they are mainly concentrated in sub-segments with relatively high prosperity in 2021, such as CRO, traditional Chinese medicine, and in vitro diagnosis
.
For example, Medicilon, whose net profit is expected to double, is a CRO for biomedical preclinical comprehensive R&D services.
Its industry is continuing the trend of rapid growth, bringing order growth to companies on the track
.
In 2021, Medicilon's newly signed orders will increase by about 88% year-on-year, continuing to benefit from the high prosperity of domestic innovative drug research and development and the continuous expansion of overseas business services
.
On the basis of the company's continuous deepening of the domestic market and the continuous development of overseas markets, some securities companies predict that the company's performance will continue to show ultra-high growth
.
WuXi AppTec's net profit in 2021 is expected to increase by about 70%.
The company mainly provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry.
Regarding the accelerated growth of sales revenue in 2021, the company said that it will always implement The strategy of "Following Molecules", the integrated chemical business (WuXi Chemistry) segment, continues to build an "integrated, end-to-end" CRDMO (Contract Research, Development and Production Organization) business, with strong demand for orders
.
In addition, the performance of the traditional Chinese medicine industry is also very bright, especially since the second half of the year, catalyzed by favorable policies, product price increases and other factors, the traditional Chinese medicine sector has risen against the trend, and related companies have also received high attention from the industry
.
Judging from the companies that have disclosed their annual report forecasts, many traditional Chinese medicine companies have also achieved certain growth
.
For example, Panlong Pharmaceutical expects its full-year net profit to increase by 9.
97%-22.
61% in 2021
.
For the main reasons for the growth in performance during the reporting period, the company stated that it was the increase in sales of self-produced products and the increase in income from the pharmaceutical distribution business
.